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Mutations in full-length HBV isolates obtained from a chronic HBV-infected patient were evaluated at three time points: 1 day, 6
months,and31months.While5nucleotidesvariation,andan18bpdeletionofpreS1havebeenkeptinduringatleasttheﬁrsttwo
years, C339T mutation occurring in the hydrophilic region of HBsAg and T770C that caused polymerase V560A substitution were
the new point mutations found existing in sequenced clones of the 3rd time point. Internal deletion of coding region obviously
appeared in the 3rd time point. The splicers included two new 5 -splice donors and three new 3 -splice acceptors besides the
reporteddonorsand acceptors and mayhaveproduced presumptiveHBV-spliced proteinsortruncated preSproteins.ALT,HBeAg
and viral DNA load varied during the follow-up years. These data demonstrated the diversity of genomes in HBV-infected patient
during evolution. Combined with clinical data, the HBV variants discovered in this patient may contribute to viral persistence of
infection or liver pathogenesis.
1.Introduction
Chronic hepatitis B virus (HBV) infection is a signiﬁcant
public health threat. Approximately 3-4 billion people
worldwide have been infected with HBV. The natural course
of chronic HBV infection is variable, ranging from an
inactiveHBsAgcarrierstatetoaprogressivechronichepatitis
which may eventually lead to cirrhosis and hepatocellular
carcinoma(HCC).Previousresearchhasshownthatpatients
with persistent HBeAg-positive state and high DNA viral
load (>106 copy/mL) are at higher risk of HCC than the
HBeAg negative individuals with low DNA viral load [1, 2].
In order to have a better understanding of this phenomenon,
we obtained HBsAg-positive serum samples from Clinical
Laboratory Center of the First People’s Hospital of Yunnan
Province, Kunming, Yunnan, China, from February to
August, 2005. We also followed up a chronically HBV-
infected patient who was HBeAg positive with high HBV
DNA load (≥107 copy/mL) for almost 3 years and studied
the evolution of her HBV strains. By sequencing and phy-
logenetic analysis, we found mutations occurred within the
genomes of HBV through time-course evolution. Combined
with clinical data, whether and how these HBV variants
might contribute to viral persistence of infection or liver
pathogenesis still needs to be further studied.
2.MaterialsandMethods
2.1. Subject and Serum Samples. A 31-year-old female with
chronic HBV infection was followed up at the First People’s
Hospital of Yunnan Province, Kunming, Yunnan, China.
The subject was admitted in the hospital because of allergic
purpura in May, 2005 and was diagnosed with chronic
infection based on the fact of having been HBsAg positive
for at least 7 years. Her serum samples were collected at three
time points after admission: 602 (1 day), 6022 (6 months),
and 6023 (two years and seven moths) and stored at −80◦C
until time of analysis. Serological markers of HBV, ALT, AST,
BIL, ALB, and GLO were analyzed at each time point. The
patient was seronegative for antibodies to HAV, HCV, HEV,
and HIV and did not have a history of alcohol abuse, drug
abuse, or hepatotoxin exposure. No antiviral treatment or2 Hepatitis Research and Treatment
Table 1: Clinic data and HBV DNA load in serum samples.
May 2005 Oct. 2005 Dec. 2007
HBsAg (OD/Cut-Oﬀ) 24.676 23.886 29.495
HBsAb (OD/Cut-Oﬀ) 0.048 0.010 0.248
HBeAg (OD/Cut-Oﬀ) 3.467 22.819 9.705
HBeAb (OD/Cut-Oﬀ) 1.869 1.785 2.385
HBcAb (OD/Cut-Oﬀ) 0 0.002 0
HBV-DNA (copy/mL−1) ∗ 2.4 ×108 2.5 ×107
ALT (U/L) (8–40)a 27 51↑ 105↑
AST (U/L) (5–40)a 26 33 47↑
T-BIL (µM) (3.4–20.5)a 12 17.2 10.6
D-BIL (µM) (0–6.8)a 34 . 9 3 . 5
I-BIL (µM) (0–13.7)a 9 12.3 7.1
TP (g/L) (65–80)a 73 71 70
ALB (g/L) (35–55)a 33 44 45
GLO (g/L) (20–30)a 40↑ 27 25
∗lack of serum.
arefernce values.
↑higher than reference values.
immunomodulators were given before or during the study
period.
2.2. Ampliﬁcation and Sequencing of Full-Length HBV
Genome. HBVDNAwasextractedfromserumbyproteinase
K digestion, followed by phenol/chloroform extraction.
Viral DNA load was determined using HBV DNA PCR-
Fluorescence Quantitation kit (Kehua Bio-Tech. Co. Ltd.,
China). The complete HBV genome was ampliﬁed by PCR
described by G¨ unther et al. [3]. The primers used were
forward primer: 5 ctttttcacctctgcctaatca3 ; reverse primer:
5 agaggtgaaaaagttgcatggt3 . Ampliﬁcation was performed in
a 96-well cycler (Bio-RAD, USA), and 25µL PCR mixture
containing 2.5mM MgCl2, 200µM dNTP, 400nM of each
primer, and 2U of Ex Taq polymerase (Takara Bio-Tech. Co.
Ltd.) was used. The PCR reaction was performed using the
following cycles: 94◦C predenature for 5min, 30 cycles of
94◦C for 1min, 56◦C for 1min, 72◦C for 2min; 72◦Cf o r
10min as a ﬁnal extension step. Then full-length amplicons
were puriﬁed using a gel extraction kit (HuaShun Bio-
Engineering Co. LTD., Shanghai, China). The PCR products
were puriﬁed and cloned in vector pMD18-T (TaKaRa Bio-
Tech. Co. Ltd.) using standard cloning techniques. White
colonies were picked, correct recombinants were conﬁrmed
by PCR, and the double-restriction endonuclease digestion
with EcoRI and Hind III. DNA sequencing analysis of the
correct recombinants was performed with BigDye Termina-
tor v3.1 and 3130 Genetic Analyzer (Applied Biosystems) (7
pairs of sequencing primers can be obtained on request). For
each time point, 8-9 recombinants were randomly selected
and sequenced.
2.3. Sequence Analysis. Fourteen HBV complete genomes
available in GenBank (genotypes A, B and E to H) were
applied to phylogenetic analysis. Additionally, 50 published
sequences of genotype C were also used in this study for
alignment analysis (Genbank accession numbers can be
obtained upon request). The whole genome sequences were
assembled by BioEdit sequence alignment editor software,
version7.0.5.2[4].AlignmentwasperformedusingClustalX
software,version1.83[5].Phylogeneticandmolecularevolu-
tionaryanalysisofnucleotidediﬀerenceswithinandbetween
the isolate sequences were carried out by MEGA program,
version 3.1 [6]. Genetic distance was estimated using the
Kimura two-parameter algorithm. The phylogenetic trees
wereconstructedbytheneighbor-joiningmethod.Bootstrap
re-sampling and reconstruction were carried out for 1,000
times to conﬁrm the reliability of phylogenetic trees.
3. Results
3.1. Clinic Data and HBV DNA Load(s) in Serum. As showed
in Table 1, HBsAg and HBeAg were positive at all three time
points and titers changed during the course of analysis. ALT
levels showed a tendency of elevation, and at the 3rd time
point the level was more than 2 times of the upper limit of
normal. While no quantiﬁcation could be obtained from the
1st time point due to the lack of serum, viral DNA load was
found to decrease from 108 to 107 copy/mL at the last two
time points.
3.2. Phylogenetic Analysis. 26 sequences were analyzed (Gen-
Bank accession number: DQ377159-377165, EU306713-
306714, EU306722–306729, EU439005, EU439008–439014
and EU439025). The divergence of these 26 sequences was
found to be 0–1.4%. When compared to the 64 complete
HBV genome sequences published in the GenBank, all
26 sequences were determined to be genotype C and C2
subgroup with a bootstrap value of 100% (data not shown).
T h es e r o t y p ew a sc l a s s i ﬁ e da sa d r q + .
3.3. Diﬀerence in Nucleotide(s). When compared with the 50
knownandcompletesequencesofgenotypeC,wefoundthat
there were 13 speciﬁc nucleotides in all sequenced clones
of this patient (data not shown). Further analysis of the
nucleotide sequence at all three time points indicated that
nucleotides T361A, C934A, C2351T/A2353T, and C2444T
were the mutation been kept in for at least two years’ evo-
lution. These mutations caused nonsense mutation of preS1
andpreCore/Coregene(T361AandC2444T,resp.),missense
mutation of precore/core and pol gene (C2351T/A2353T
and C934A, resp.). Nucleotides C339T and T770C were the
new and major mutation at the 3rd time point, and these
mutations caused HBsAg P62L and polymerase (Pol) V560A
mutation, respectively (Figure 1). Premature stop codons
of S gene (g.200C>T, g.565T>A, g.361T>A, g.455C>T, and
g.304 305CC>TT) increased during the course(1/9 versus
3/9 versus 6/8) (Figure 2). A1762T/G1764A double mutation
existed in allclones, and G1896A existed in 4clones obtained
from all time points.
3.4. Defective Genomes during the HBV Evolution. Per-
forming alignment showed that over the 2-year period,
deletions across overlapping region of polymerase/preS1
(g.2447 489del 1256) or preS1/preS2 (g.3018 3202del 183,Hepatitis Research and Treatment 3
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Figure 1: Partial nucleotide sequences of all the 26 clones obtained from three time points. Black bars indicate the major mutation during
this period of time. The variants include nucleotide substitution and deletion. 602 (1st time point, 1 day); 6022 (2nd time point, 6 months);
6023 (3rd time point, 31 months).
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Figure 2: Full-length nucleotide sequences of all the 26 clones obtained from three time points. 602 (1st time point, 1 day); 6022 (2nd time
point, 6 months); 6023 (3rd time point, 31 months). The length of these clones varied from 3254bp to 1959bp, which were caused by the
insertionanddeletion.PrematurestopcodonsofSgene(g.200C>T,g.565T>A,g.361T>A,g.455C>T,andg.304 305CC>TT)arealsoshown.4 Hepatitis Research and Treatment
and g.3144 56del 126), and pre-S1 initiation codon muta-
tions (g.2846 2865del 18) with or without internal deletions
mutations (g.3024 3193del 168) were prevalent (22/26, in
85% of the clones) (Figure 2). All the defective genomes
shared sequences from nucleotide position 489 to position
2447, and common to all genomes is the presence of the
complete X gene and the complete C ORF. Four paires of
donor/acceptor were found in the spliced genomes, besides
the frequently reported donor sites 2447 and 3018 and the
acceptor sites 489, two new 5 -splice donors (nt3144 and
3024) and three new 3 -splice acceptors (nt56, 3193 and
3202) were detected at the 3rd time.
4. Discussion
Up until now, details of the mechanism accounted for the
HBV evolution remained unknown. In this study, we fol-
lowed up a chronically HBV-infected patient and discovered
that complex and diverse quasispecies existed in this patient
for over two-year disease evolution. Based on the alignment
and phylogenetic analyses, the divergence and the 13 speciﬁc
nucleotides of the 26 clones, as well as the phylogenic
analysisitisindicatedthatallsequencesweredirectlydescent
from the common ancestor. Thus, these results reﬂect the
real evolution process of homogeneous HBV strains in this
patient.
4.1. Signiﬁcance of Nonsense Mutations of PreS1/S2/S Gene.
In the process of evolution, some mutations in this patient
were kept in for at least 2 years, and other new mutations
emerged at the 3rd time point. These mutations resulted
in amino acids substitutions and some caused premature
stop codon of the coding regions. Among these mutants,
the T361A nonsense mutation in the small S region, which
resulted in a 69aa truncated HBsAg lacking the entire
“a” determinant region (aa124–147), was ﬁrst detected at
the 2nd time point in one clone. At the 3rd time point,
however, half of the sequenced clones were found to have
this mutation. This mutant has been reported in the occult
HBV-infected patients with seronegative for HBsAg, and
in one case HBV DNA was absent from the serum after
the two-year [7, 8]. In our case, after two-year followup,
the HBsAg was still at a high level and could be detected
by routine immunoassay-based diagnosis. In addition, HBV
DNA was at a high load despite a slightly decreased level
(2.4 × 108 versus 2.5 × 107 copy/mL), and the ALT level
showed an elevating trend over the study period. In the
meanwhile, new point mutations such as C339T and T770C
were detected at the 3rd time point; the former occurred in
thehydrophilicregionofHBsAgandthelatterwaspreviously
discovered in a HCC patient (Genbank number AY206393).
We speculated that these mutants might aﬀord HBV variants
a distinct survival advantage by allowing the mutant virus
to escape from the immune system. In addition, these
mutations could further transactivate certain oncogenes
which in turn rendered the acceleration of the liver damage
[9–13].
4.2. An 18bp Deletion of PreS1. In this patient, we found an
18bp deletion of preS1 that was kept in. The deletion region
is in the span of hepatocellular-binding site (aa5–20) and
led to aa1–11 deletion in preS1. This deletion mutant was
previously reported in diﬀerent clinical cases and genotypes
[14–17]. For example, this 18bp deletion was detected in
a heart transplant patient while it was not found with the
donor [18]. In our case, retrospective study showed that the
son of this patient, though infected with HBV via mother-
to-infant transmission, carried none of these mutant strains
in the sequenced clones [19]. This phenomenon may imply
that host immune pressure was the primary cause of aa1–11
deletion in preS1. In addition, this mutant seemed to have
reduced from the 1st time point to the 3rd time point (7/9
versus 7/9 versus 2/8) and had a tendency to be substituted
by large fragments deletion located in the preS region at the
3rd time point (Figure 2). Whether it was a precursor of
large fragment deletion mutation or just an isolated event
happened under the immune pressure still needed to be
carefully studied.
4.3. Defective Genomes during the HBV Evolution. The
other prominent variation at the 3rd time point was the
defective genomes caused by the large fragment deletion
focused on the overlapping regions of polymerase/preS1
and preS1/preS2. The length of internal deletions was
from 126bp to 1256bp. Up until now, there have been
at least 15 types of spliced HBV DNA reported in the
literature (Figure 3)[ 20, 21], which consisted of seven
5 -splice donors and six 3 -splice accepters. In our case,
four types of spliced HBV DNA were found at the 3rd
time point, the donor site and the receptor site of these
splicers followed the GT-AT rules [22]. Among them,
the 2447/489 donor/acceptor splicer existed as described
in previous reports and produced a presumptive HBV
spliced protein (HBSP) [23]. In addition, positions 3144
and 3024 as the 5 -donor sites and positions 3202, 3193,
and 56 as the 3 -acceptor sites were ﬁrst reported in our
study. During a subsequence screening, we also detected
defective genomes in patients with hepatocirrhosis and
CHB (GenBank accesson numbers: EU439017, EU306668,
EU306669,EU330986,EU306676,EU306670).Thoughthese
defective genomes were diﬀerent in structure, they all
shared sequences from nucleotides position 489 to position
2447. This region contains all known signals required for
conventional replication (DR1 and DR2), synthesis, and
processing of pregenomic/C-mRNA, preC mRNA, and X
mRNA, and pregenomic RNA encapsidation. In contrast,
all lacked the complete pre-S1 and, or pre-S2 ORFs. Many
surveys noted that spliced HBV DNA and pre-S deletion
were more frequently detected in patients with severe liver
disease [24–26] and often existed during the process of anti-
HBe seroconversion and subsequent loss of HBsAg [27–29].
However, in this case with our subsequent screening, all
the patients with defective genomes were HBeAg positive
and with high HBV DNA load (≥107 copy/mL). Based on
these ﬁndings, we deduced that these defective genomes
(with intact X gene and all signals required for viral lifeHepatitis Research and Treatment 5
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Figure 3:HBVsplicedvariants.Therewere15typesofsplicerreportedintheliterature,includingseven5 -splicesitesatnucleotidepositions
2447, 2067, 2985, 3018, 2087, 2471, 458; six 3 -splice sites at nucleotide positions 489, 2350, 2902, 2935, 282, 1308. In this report, 3 new
splicers were detected, including two new 5 –splice donors (nt3144 and 3024) and three new 3 -splice acceptors (nt56, 3193, and 3202).
cycle) might contribute to persistent HBV replication in the
patient.
4.4. Mutations Scattered in the Whole Genomes. Other
mutations such as C934A, C2351T/A2353T, C2444T,
A1762T/G1764A, and G1896A were scattered in the whole
genomes. In the present study, all clones of the mother
from three time points had double mutations of nucleotide
A1762T/G1764A in basal core promoter (BCP), four of
which were also coupled with G1896A. However, we did not
observe any HBeAg/anti-HBeAg seroconversion at the three
time points, nor did we detect the impact of BCP mutation
on HBV DNA load [30, 31]. In addition, multisequences
alignment has showed that genotype C had a tendency
for higher prevalence of the BCP mutation (41 versus 35,
53.9%) (GenBank accesson number can be obtained on
request). Combined with the clinic results (Table 1), whether
the BCP and precore mutations in this patient were related
to infection with genotype C, or whether the patient was
seroconverting to anti-HBeAg or may develop severe disease
[32, 33] are questions that still need to be followedup.
Inconclusion,ourdatashowedthatviralquasispeciesare
very closely related to genomes but exist in an environment
of mutation, selection, and competition, and thus lead to
a dynamic and changing population. During this progress,
some mutations were kept in and became the dominant
strains, some new mutations emerged, and these strains may
play important roles in the persistence of infection or the
progression of disease.
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